Mesa Laboratories Inc: Form 10-K for the period ended Mar 31, 2023
Filed with the SEC on May 30, 2023 and accepted by EDGAR at May 30, 2023, 08:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2022-04-01 to 2023-03-31 | $219.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2022-04-01 to 2023-03-31 | $85.4m | us-gaap:CostOfRevenue |
| Gross profit | 12 months2022-04-01 to 2023-03-31 | $133.7m | us-gaap:GrossProfit |
| Research and development | 12 months2022-04-01 to 2023-03-31 | $20.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2022-04-01 to 2023-03-31 | $3.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2022-04-01 to 2023-03-31 | $4.8m | us-gaap:InterestExpense |
| Income tax | 12 months2022-04-01 to 2023-03-31 | −$1.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2022-04-01 to 2023-03-31 | $930.0k | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2022-04-01 to 2023-03-31 | $0.17 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2022-04-01 to 2023-03-31 | $0.17 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2022-04-01 to 2023-03-31 | 5,361,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2022-04-01 to 2023-03-31 | $28.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2022-04-01 to 2023-03-31 | $4.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months2022-04-01 to 2023-03-31 | $3.4m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2023-03-31 | $32.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $119.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $661.8m | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $43.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-03-31 | $268.4m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-03-31 | $393.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-23-016028. Last ingested by Listed: Oct 29, 2026, 18:36 ET. Listed shows no prices and gives no investment advice.